文献速递心外重症与机械循环支持

扩展标准供体使用先进心脏保存技术的受体结局:GUARDIAN-Heart注册分析

Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry.
PubMed 文献 · J Heart Lung Transplant · 2023-12-30

基于GUARDIAN-Heart注册,2015年10月至2022年12月15个美国中心1113例成人心脏移植受者中,扩展标准供体亚组(SherpaPak 193例、冰存137例)分析显示,SherpaPak组移植后机械循环支持使用率、新发ECMO/VAD及严重原发性移植物功能障碍均显著低于冰存组,1年生存率两组相似。

要点

  • 扩展标准供体亚组中,SherpaPak组移植后机械循环支持使用率22.3% vs 冰存组35.0%,p=0.012。
  • SherpaPak组新发ECMO/VAD 7.8% vs 冰存组15.3%,p=0.033;严重原发性移植物功能障碍6.2% vs 13.9%,p=0.022。
  • 两组1年生存率相似:SherpaPak组92.9% vs 冰存组89.6%,p=0.27。

核心结论

  • 该亚组分析表明,SherpaPak可安全用于扩展标准供体,严重原发性移植物功能障碍发生率低。

研究设计与样本

  • GUARDIAN-Heart注册的汇总统计分析,纳入2015年10月至2022年12月15个美国中心的1113例成人心脏移植受者,使用SherpaPak(n=560)或传统冰存(ice,n=453)。
  • 采用既往发表的标准识别扩展标准供体,其中SherpaPak组193例、冰存组137例。

主要发现

  • 两队列受者基线存在少数差异,最突出的是SherpaPak组IMPACT评分、转运距离和总缺血时间显著更高,且SherpaPak组总缺血时间>4小时的供心显著更多。
  • 移植后机械循环支持使用率SherpaPak组22.3% vs 冰存组35.0%(p=0.012),SherpaPak组显著降低。
  • 新发体外膜肺氧合/心室辅助装置(ECMO/VAD)SherpaPak组7.8% vs 冰存组15.3%(p=0.033),SherpaPak组显著降低。
  • 严重原发性移植物功能障碍SherpaPak组6.2% vs 冰存组13.9%(p=0.022),SherpaPak组显著降低超过50%。
  • 两队列1年生存率相似:SherpaPak组92.9% vs 冰存组89.6%(p=0.27)。

临床怎么用

  • 原文未据此给出推荐;原文结论为SherpaPak可安全用于扩展标准供体,严重原发性移植物功能障碍发生率低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of end-stage heart failure and patients who could benefit from heart transplantation requires an expansion of the donor pool, relying on the transplant community to continually re-evaluate and expand the use of extended criteria donor organs. Introduction of new technologies such as the Paragonix SherpaPak Cardiac Transport System aids in this shift. We seek to analyze the impact of the SherpaPak system on recipient outcomes who receive extended criteria organs in the GUARDIAN-Heart Registry. METHODS: Between October 2015 and December 2022, 1,113 adults from 15 US centers receiving donor hearts utilizing either SherpaPak (n = 560) or conventional ice storage (ice, n = 453) were analyzed from the GUARDIAN-Heart Registry using summary statistics. A previously published set of criteria was used to identify extended criteria donors, which included 193 SherpaPak and 137 ice. RESULTS: There were a few baseline differences among recipients in the 2 cohorts; most notably, IMPACT scores, distance traveled, and total ischemic time were significantly greater in SherpaPak, and significantly more donor hearts in the SherpaPak cohort had >4 hours total ischemia time. Posttransplant mechanical circulatory support utilization (SherpaPak 22.3% vs ice 35.0%, p = 0.012) and new extracorporeal membrane oxygenation/ventricular assist device (SherpaPak 7.8% vs ice 15.3%, p = 0.033) was significantly reduced, and the rate of severe primary graft dysfunction (SherpaPak 6.2% vs ice 13.9%, p = 0.022) was significantly reduced by over 50% in hearts preserved using SherpaPak. One-year survival between cohorts was similar (SherpaPak 92.9% vs ice 89.6%, p = 0.27). CONCLUSIONS: This subgroup analysis demonstrates that SherpaPak can be safely used to utilize extended criteria donors with low severe PGD rates.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Moayedifar R, Shudo Y, Kawabori M, et al. Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry. J Heart Lung Transplant. 2023. PMID: 38163452. doi:10.1016/j.healun.2023.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。